{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:10:30Z","timestamp":1793920230137,"version":"4.8.0"},"reference-count":68,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,12,14]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriatic arthritis (PsA) is a complex, immune-mediated disease associated with skin psoriasis that, if left untreated, can lead to joint destruction. Up to 30% of patients with psoriasis progress to PsA. In most cases, psoriasis precedes synovio-entheseal inflammation by an average of 5\u20137 years, providing a unique opportunity for early and potentially preventive intervention in a susceptible and identifiable population. Guselkumab is an effective IL-23p19 inhibitor Food and Drug Administration (FDA)-approved for treatment of moderate-to-severe psoriasis and PsA. The Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA) study aims to evaluate the efficacy of guselkumab in preventing PsA and decreasing musculoskeletal power Doppler ultrasound (PDUS) abnormalities in a population of patients with psoriasis who are at-increased risk for PsA progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The PAMPA study is a multicentre, randomised, double-blind, placebo-controlled, interventional, preventive trial comparing PDUS involvement and conversion to PsA in patients with psoriasis at-increased risk for progression treated with guselkumab compared with non-biological standard of care. The study includes a screening period, a double-blind treatment period (24 weeks) and an open-label follow-up period (72 weeks). At baseline, 200 subjects will be randomised (1:1) to receive either guselkumab 100\u2009mg (arm 1) or placebo switching to guselkumab 100\u2009mg starting at week 24 (arm 2). Arm 3 will follow 150 at-risk psoriasis patients who decline biological therapy and randomisation. Changes from baseline in the PDUS score at week 24 and the difference in proportion of patients transitioning to PsA at 96 weeks will be examined as the coprimary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval for this study was granted by the coordinating centre\u2019s (NYU School of Medicine) Institutional Review Board (IRB). Each participating site received approval through their own IRBs. The findings will be shared in peer-reviewed articles and scientific conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05004727\">NCT05004727<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-063650","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:55:46Z","timestamp":1671796546000},"page":"e063650","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct05004727","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03030118","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02603146","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7119-8136","authenticated-orcid":false,"given":"Rebecca H","family":"Haberman","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina A","family":"MacFarlane","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Catron","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Samuels","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca B","family":"Blank","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Toprover","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakwan","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinty","family":"Gong","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Tausk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L","family":"Neimann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Gulliver","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf G","family":"Thiele","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology\/Department of Medicine\/Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Memorial University of Newfoundland, St. John\u2019s, NL, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, University of Toronto and Women\u2019s College Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"C T","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U","family":"Scher","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, New York University Grossman School of Medicine and Psoriatic Arthritis Center, NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"key":"2025121401334937000_12.12.e063650.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"2025121401334937000_12.12.e063650.2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121401334937000_12.12.e063650.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20401"},{"key":"2025121401334937000_12.12.e063650.4","first-page":"680","article-title":"The burden of psoriatic arthritis: a literature review from a global health systems perspective","volume":"35","author":"Lee","year":"2010","journal-title":"P T"},{"key":"2025121401334937000_12.12.e063650.5","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T"},{"key":"2025121401334937000_12.12.e063650.6","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"2025121401334937000_12.12.e063650.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu264"},{"key":"2025121401334937000_12.12.e063650.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"2025121401334937000_12.12.e063650.9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National psoriasis Foundation surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2025121401334937000_12.12.e063650.10","doi-asserted-by":"crossref","unstructured":"Scher JU . The 2018 landscape of RA, PSA, and SpA pathogenesis. Curr Opin Rheumatol 2017.doi:10.1097\/BOR.0000000000000461","DOI":"10.1097\/BOR.0000000000000461"},{"key":"2025121401334937000_12.12.e063650.11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the medical Board of the National psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025121401334937000_12.12.e063650.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025121401334937000_12.12.e063650.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025121401334937000_12.12.e063650.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025121401334937000_12.12.e063650.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-019-0876-z","article-title":"Strategies to improve outcomes in psoriatic arthritis","volume":"21","author":"Ritchlin","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2025121401334937000_12.12.e063650.16","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1093\/rheumatology\/keaa880","article-title":"Induction of remission in biologic-naive, severe psoriasis and PSA with dual anti-cytokine combination","volume":"60","author":"Haberman","year":"2021","journal-title":"Rheumatology"},{"key":"2025121401334937000_12.12.e063650.17","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.6"},{"key":"2025121401334937000_12.12.e063650.18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrrheum.2013.184","article-title":"Autoantibodies and SLE: the threshold for disease","volume":"10","author":"Olsen","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"2025121401334937000_12.12.e063650.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31491-5"},{"key":"2025121401334937000_12.12.e063650.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212763"},{"key":"2025121401334937000_12.12.e063650.21","unstructured":"Study of anti-malarials in incomplete lupus erythematosus (SMILE). Available: https:\/\/clinicaltrials.gov\/show\/NCT03030118"},{"key":"2025121401334937000_12.12.e063650.22","unstructured":"Strategy to prevent the onset of clinically-apparent rheumatoid arthritis (StopRA). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02603146"},{"key":"2025121401334937000_12.12.e063650.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3403-7"},{"key":"2025121401334937000_12.12.e063650.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0"},{"key":"2025121401334937000_12.12.e063650.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00578-2"},{"key":"2025121401334937000_12.12.e063650.26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201273"},{"key":"2025121401334937000_12.12.e063650.28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.24172"},{"key":"2025121401334937000_12.12.e063650.30","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.141"},{"key":"2025121401334937000_12.12.e063650.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089367"},{"key":"2025121401334937000_12.12.e063650.32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06672-6","article-title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","volume":"9","author":"Patrick","year":"2018","journal-title":"Nat Commun"},{"key":"2025121401334937000_12.12.e063650.33","doi-asserted-by":"crossref","unstructured":"Simon D , Tascilar K , Kleyer A , et al . Structural entheseal lesions in patients with psoriasis are associated with an increased risk of progression to psoriatic arthritis. Arthritis Rheumatol 2020;72.","DOI":"10.1136\/annrheumdis-2020-eular.1524"},{"key":"2025121401334937000_12.12.e063650.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208821"},{"key":"2025121401334937000_12.12.e063650.35","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2521"},{"key":"2025121401334937000_12.12.e063650.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"2025121401334937000_12.12.e063650.37","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0476-2"},{"key":"2025121401334937000_12.12.e063650.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2025121401334937000_12.12.e063650.39","unstructured":"R Core Team . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing."},{"key":"2025121401334937000_12.12.e063650.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121401334937000_12.12.e063650.41","unstructured":"Thiele RG , Chiu YG , Huertas N , et al . Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls [abstract]. Arthritis Rheumatol 2018;70."},{"key":"2025121401334937000_12.12.e063650.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101119"},{"key":"2025121401334937000_12.12.e063650.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2025121401334937000_12.12.e063650.44","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1957-0"},{"key":"2025121401334937000_12.12.e063650.45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/art.40778","article-title":"Regression of peripheral subclinical enthesopathy in therapy\u2010naive patients treated with Ustekinumab for moderate\u2010to\u2010severe chronic plaque psoriasis: a fifty\u2010two\u2013week, prospective, open\u2010label feasibility study","volume":"71","author":"Savage","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220761"},{"key":"2025121401334937000_12.12.e063650.47","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025121401334937000_12.12.e063650.48","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025121401334937000_12.12.e063650.49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case\u2013control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States","volume":"86","author":"Merola","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025121401334937000_12.12.e063650.51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41584-021-00706-y","article-title":"Does psoriasis treatment affect PSA development?","volume":"17","author":"Merola","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025121401334937000_12.12.e063650.52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070663"},{"key":"2025121401334937000_12.12.e063650.53","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132710"},{"key":"2025121401334937000_12.12.e063650.54","doi-asserted-by":"publisher","DOI":"10.1002\/art.27622"},{"key":"2025121401334937000_12.12.e063650.55","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120234"},{"key":"2025121401334937000_12.12.e063650.56","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.57","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010641"},{"key":"2025121401334937000_12.12.e063650.58","doi-asserted-by":"publisher","DOI":"10.1186\/ar3781"},{"key":"2025121401334937000_12.12.e063650.59","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"2025121401334937000_12.12.e063650.60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5145"},{"key":"2025121401334937000_12.12.e063650.61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69537-3","article-title":"Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new psoriasis-microbiome index","volume":"10","author":"Dei-Cas","year":"2020","journal-title":"Sci Rep"},{"key":"2025121401334937000_12.12.e063650.62","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.643449","article-title":"Microbiome and metabolome analyses reveal novel interplay between the skin microbiota and plasma metabolites in psoriasis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Microbiol"},{"key":"2025121401334937000_12.12.e063650.63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083998","article-title":"Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis","volume":"22","author":"Olejniczak-Staruch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025121401334937000_12.12.e063650.64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.65","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.41169","article-title":"Interleukin\u201017 inhibition in spondyloarthritis is associated with subclinical gut microbiome perturbations and a distinctive Interleukin\u201025\u2013Driven intestinal inflammation","volume":"72","author":"Manasson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025121401334937000_12.12.e063650.66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"2025121401334937000_12.12.e063650.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"2025121401334937000_12.12.e063650.68","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201532"}],"updated-by":[{"DOI":"10.1136\/bmjopen-2022-063650corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000}}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-063650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:34:03Z","timestamp":1765704843000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-063650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":68,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,23]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/bmjopen-2022-063650"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-063650","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}